Integra Lifesciences Holdings (IART) Short term Debt (2009 - 2026)

Integra Lifesciences Holdings has disclosed Short term Debt across 16 years of filings, most recently posting $43.6 million for Q2 2026.

• In Q2 2026, Short term Debt fell 92.41% year-over-year to $43.6 million; the TTM figure through Jun 2026 stood at $43.6 million (down 92.41% YoY), while the FY2025 annual figure was $87.8 million, down 84.68% from the prior year.
• Short term Debt came in at $43.6 million for Q2 2026 at Integra Lifesciences Holdings, up from $38.8 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $574.6 million in Q2 2025 to a low of $38.8 million in Q3 2025.
• Average Short term Debt over 5 years is $192.7 million, with a median of $98.6 million recorded in 2023.
• Year-over-year, Short term Debt jumped 656.2% in 2024 and slumped 93.25% in 2026.
• Over 5 years, Short term Debt stood at $104.7 million in 2022, then dropped by 14.8% to $89.2 million in 2023, then jumped by 542.57% to $573.2 million in 2024, then tumbled by 84.68% to $87.8 million in 2025, then tumbled by 50.35% to $43.6 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $43.6 million in Q2 2026, $38.8 million in Q1 2026, and $87.8 million in Q4 2025.